Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
Opinion|Articles|June 22, 2026
ASCO 2026 Lung Cancer Abstracts: Clinical Practice Implications
Author(s)Missak Haigentz, MD
Fact checked by: Sabrina Serani
Dr Haigentz breaks down 3 practice-changing ASCO 2026 lung cancer abstracts, from adjuvant targeted therapy to ADCs reshaping the immunotherapy backbone.
Advertisement
Advertisement
Every ASCO Annual Meeting brings a wave of new data, but only a handful of abstracts truly shift how practice. Missak Haigentz, MD, chief of Thoracic Medical Oncology and chief of Head & Neck Medical Oncology, Rutgers Cancer Institute/Jack & Sheryl Morris Cancer Center, discusses the 3 abstracts he considers to be standouts from this year’s meeting.
Related to this article
The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
In the phase 3 EXCALIBER-RRMM trial, iberdomide plus daratumumab and dexamethasone doubled MRD-negative complete response rates over standard therapy in relapsed myeloma.
Closing sessions at IMS 2026 featured MRD-guided treatment strategies, real-world CAR T-cell data, and mixed results on cilta-cel neurotoxicity prevention in myeloma.
Etentamig significantly improved response and survival over standard therapy in the phase 3 CERVINO trial, headlining day 3 of IMS 2026 myeloma coverage.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
US cancer deaths keep falling as lung cancer declines; smoking drops, screening rises, but rural and low-education gaps persist.
Half of patients who stopped MRD-guided maintenance in GEM2014MAIN remained progression-free at 7 years, as IMS 2026 also featured DREAMM-9, MIDAS, and novel bispecific data.
Advertisement
Advertisement